Gerocilan 20 mg filmom obalené tablety 슬로바키아 - 슬로바키아어 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

gerocilan 20 mg filmom obalené tablety

g.l. pharma gmbh, rakúsko - tadalafil - 83 - vasodilatantia

ZENAVIL 20 mg filmom obalené tablety 슬로바키아 - 슬로바키아어 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

zenavil 20 mg filmom obalené tablety

medochemie ltd., cyprus - tadalafil - 83 - vasodilatantia

ZENAVIL 5 mg filmom obalené tablety 슬로바키아 - 슬로바키아어 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

zenavil 5 mg filmom obalené tablety

medochemie ltd., cyprus - tadalafil - 83 - vasodilatantia

Rekifre 20 mg filmom obalené tablety 슬로바키아 - 슬로바키아어 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

rekifre 20 mg filmom obalené tablety

neuraxpharm bohemia s.r.o., Česká republika - tadalafil - 83 - vasodilatantia

Tadulan 20 mg 슬로바키아 - 슬로바키아어 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

tadulan 20 mg

stada arzneimittel ag, nemecko - tadalafil - 83 - vasodilatantia

Tadulan 5 mg 슬로바키아 - 슬로바키아어 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

tadulan 5 mg

stada arzneimittel ag, nemecko - tadalafil - 83 - vasodilatantia

Tadard 20 mg 슬로바키아 - 슬로바키아어 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

tadard 20 mg

ardez pharma, spol. s r.o., Česká republika - tadalafil - 83 - vasodilatantia

TALAFT 20 mg 슬로바키아 - 슬로바키아어 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

talaft 20 mg

biodemada sp. z o. o., poľsko - tadalafil - 83 - vasodilatantia

TALAFT 5 mg 슬로바키아 - 슬로바키아어 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

talaft 5 mg

biodemada sp. z o. o., poľsko - tadalafil - 83 - vasodilatantia

Volibris 유럽 연합 - 슬로바키아어 - EMA (European Medicines Agency)

volibris

glaxosmithkline (ireland) limited - ambrisentan - hypertenzia, pľúca - antihypertenzív, - volibris is indicated for treatment of pulmonary arterial hypertension (pah) in adult patients of who functional class (fc) ii to iii, including use in combination treatment (see section 5.  efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease. volibris is indicated for treatment of pah in adolescents and children (aged 8 to less than 18 years) of who functional class (fc) ii to iii including use in combination treatment. efficacy has been shown in ipah, familial, corrected congenital and in pah associated with connective tissue disease (see section 5.